Core Viewpoint - The company expects to achieve a positive net profit in 2025, marking a turnaround from previous losses, with a projected net profit attributable to shareholders ranging from 13.77 million to 20 million yuan, compared to a loss of 68.85 million yuan in the same period last year [1] Financial Performance - The anticipated net profit for 2025 is between 13.77 million and 20 million yuan, indicating a significant improvement from the previous year's loss of 68.85 million yuan [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between -28.69 million and -23.47 million yuan, reflecting a decline of 299.58% to 343.93% compared to the previous year [1] Investment Gains - The increase in financial asset fair value changes and investment income from joint ventures is the primary reason for the expected improvement in net profit [1] - The company’s investments in financial assets, mainly in biopharmaceuticals, medical devices, and health-related investment funds, contributed approximately 19 million yuan in fair value gains and joint venture income, representing an increase of about 110% [1]

Financial Performance - The company expects a net profit attributable to shareholders of approximately ¥13.77 million for 2025, compared to a loss of ¥68.85 million in the same period last year, indicating a turnaround [5]. - The net profit excluding non-recurring gains and losses is projected to be approximately -¥28.69 million, a decrease of 299.58% compared to -¥23.47 million last year [5]. - The increase in net profit is primarily due to a rise in fair value changes of financial assets and investment income from joint ventures, estimated at ¥19 million, representing a 110% increase [7]. - The company anticipates non-recurring gains and losses to impact net profit by approximately ¥43 million, mainly from fair value changes and investment income from trading financial assets [8]. - The financial data presented is preliminary and has not been audited, with detailed figures to be disclosed in the 2025 annual report [9].

Group 1 - The core point of the article is that Sai Sheng Pharmaceutical (300485) reported a total of 34,145 shareholders as of January 20, 2026 [1]

Group 1 - The core viewpoint of the article is that Sai Sheng Pharmaceutical (300485.SZ) has a subsidiary that offers products for treating influenza, but these products contribute a small portion to the company's main business revenue [1] - The company emphasizes that the use of its influenza products must follow medical advice, indicating a focus on responsible usage [1] - Investors are advised to be aware of the investment risks associated with the limited revenue contribution from the influenza product line [1]

Group 1 - The core viewpoint of the article is that Sai Sheng Pharmaceutical (300485.SZ) has indicated through its investor interaction platform that its subsidiary possesses products for treating influenza, but the revenue from these products constitutes a small portion of its main business income [1] - The company emphasizes that the use of its influenza-related products must adhere to medical advice [1] - Investors are advised to be cautious regarding investment risks associated with the company's influenza products due to their limited contribution to overall revenue [1]

Group 1 - The company, Saiseng Pharmaceutical, announced a change in the project partner for the audit of its 2025 financial statements and internal controls from Liu Junshan to Yan Lei due to internal adjustments at the auditing firm, Deloitte [2]

Group 1 - The controlling shareholder's actual controller, Ma Li, plans to reduce holdings from October 21, 2025, to January 20, 2026, by no more than 9.6333 million shares, accounting for 2% of the company's total share capital [1] - As of January 20, 2026, Ma Li has reduced holdings by 6.41 million shares, which is 1.33% of the total shares, through centralized bidding and block trading [1] - The reduction included selling 4.81 million shares at 12.07 yuan per share from November 18, 2025, to January 14, 2026, and 1.6 million shares at 10.36 yuan per share from January 13 to January 19, 2026 [1] Group 2 - Liu Shuqin has not reduced any holdings, and the reduction plan period has expired [1]

Group 1 - The company, Sai Sheng Pharmaceutical, announced that its subsidiary, Beijing Sai Er Biological Pharmaceutical Co., Ltd., has recently received the high-tech enterprise certificate from the Beijing Science and Technology Commission, Beijing Finance Bureau, and the State Taxation Administration of Beijing [2] - This certificate is a re-certification following the expiration of the previous one, allowing the company to pay corporate income tax at a rate of 15% for the fiscal years 2025 to 2027 [2]

北京赛升药业股份有限公司（以下简称"公司"）于 2025 年 9 月 19 日在巨 潮资讯网披露了《关于公司控股股东、实际控制人的一致行动人减持股份的预披 露公告》（公告编号：2025-036）。马丽女士和刘淑芹女士因自身资金需求拟通 过集中竞价交易方式、大宗交易方式等深圳证券交易所认可的合法方式减持股份 数量合计不超过 9,633,328 股，即不超过公司目前总股本的 2%。减持期间为自 本公告披露之日起 15 个交易日后的三个月内（即 2025 年 10 月 21 日至 2026 年 1 月 20 日）。 证券代码：300485 证券简称：赛升药业 公告编号：2026-004 北京赛升药业股份有限公司 关于公司控股股东、实际控制人的一致行动人 减持计划期限届满暨减持股份实施情况的公告 公司控股股东、实际控制人的一致行动人马丽女士保证向本公司提供的信息内容 真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、本次减持计划的实施符合《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》《上市公司股东、董监 ...

Core Viewpoint - Sai Sheng Pharmaceutical (300485.SZ) has received the "High-tech Enterprise Certificate" from the Beijing Municipal Science and Technology Commission, which allows its subsidiary, Beijing Sai Er Biological Pharmaceutical Co., Ltd., to benefit from tax incentives for high-tech enterprises for three years [1] Group 1 - The certificate number is GR202511004935, issued on December 2, 2025, and is valid for three years [1] - The recognition as a high-tech enterprise is a re-certification following the expiration of the previous certificate [1] - From the year of recognition, Sai Er Biological will enjoy a corporate income tax rate of 15% for the years 2025, 2026, and 2027, in accordance with national tax incentive policies for high-tech enterprises [1]